Immunogenicity and Safety of Tetravalent Dengue Vaccine Given in 1 , 2 , or 3 Dose Schedules (STAGE I) Followed by a Single Booster Injection of the Same Vaccine (STAGE II) 1 or 2 Years After the Last Primary Dose in Healthy Subjects 9 to 50 Years of Age in Colombia and the Philippines
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Jul 2017
At a glance
- Drugs CYD TDV (Primary)
- Indications Dengue
- Focus Pharmacodynamics
- Sponsors sanofi pasteur
- 28 Jun 2017 Planned End Date changed from 1 Jul 2020 to 19 Mar 2020.
- 28 Jun 2017 Planned primary completion date changed from 1 Feb 2020 to 19 Mar 2020.
- 22 Sep 2016 Status changed from recruiting to active, no longer recruiting.